Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases
This retrospective investigation supports the notion of potential benefits associated with sequential administration of ICI and denosumab, although statistical significance was not achieved. Future studies, including prospective trials or updated retrospective analyses, focusing on cancers treated with first-line immunotherapy, could provide further insights into this therapeutic approach.
Authors
- Julien Péron (ORCID: https://orcid.org/0000-0002-1709-5152)
- Denis Maillet (ORCID: https://orcid.org/0000-0001-6883-2696)
- Philippe Clézardin (ORCID: https://orcid.org/0000-0003-0149-4463)
- Emmanuel Massy (ORCID: https://orcid.org/0000-0002-4842-8618)
- Emmanuel Grolleau (ORCID: https://orcid.org/0000-0001-7045-9819)
- Stéphane Dalle (ORCID: https://orcid.org/0000-0002-3423-4548)
- Edith Bonnelye (ORCID: https://orcid.org/0000-0003-2574-1246)
- S. Mainbourg
- E. Mabrut
- Clara Fontaine Delaruelle
- Christian Confavreux
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université de Lille (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Lyon Sud (FR)
- Physiopathologie, diagnostic et traitements des maladies musculo-squelettiques (FR)
- HCL Technologies (India) (IN)
Publication Details
- Journal
- Journal of bone oncology
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1016/j.jbo.2024.100634
- Citations
- 6
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.70